Cargando…

Plasminogen activator inhibitor 1 and 2 are tumor necrosis factor/cachectin-responsive genes

Human rTNF/Cachectin was shown to stimulate gene transcription of plasminogen activator inhibitor (PA1)-1 and PAI-2, and simultaneously suppress constitutive gene expression of tissue-type plasminogen activator (t-PA) in human fibrosarcoma cells. We propose that a TNF- mediated reprogramming of gene...

Descripción completa

Detalles Bibliográficos
Formato:	Texto
Lenguaje:	English
Publicado:	The Rockefeller University Press 1988
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2188989/ https://www.ncbi.nlm.nih.gov/pubmed/3137305

Ejemplares similares

Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation
Publicado: (1988)

Circadian dynamics of tumor necrosis factor alpha (cachectin) lethality
Publicado: (1994)

Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1
Publicado: (1986)

Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses
Publicado: (1988)

Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice
Publicado: (1988)

Tumor necrosis factor alpha/cachectin and interleukin 1 beta initiate meningeal inflammation
Publicado: (1990)

Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1
Publicado: (1986)

Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas
Publicado: (1988)

Cachectin/tumor necrosis factor mediates changes of skeletal muscle plasma membrane potential
Publicado: (1986)

Raised serum levels of cachectin/tumor necrosis factor alpha in renal allograft rejection
Publicado: (1987)

Production of tumor necrosis factor/cachectin by human B cell lines and tonsillar B cells
Publicado: (1988)

Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis
Publicado: (1989)

Tumor necrosis factor alpha/cachectin is a growth factor for thymocytes. Synergistic interactions with other cytokines
Publicado: (1988)

Tumor necrosis factor/cachectin. Induction of hemorrhagic necrosis in normal tissue requires the fifth component of complement (C5)
Publicado: (1988)

Tumor necrosis factor alpha/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium
Publicado: (1990)

Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia
Publicado: (1989)

Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts
Publicado: (1985)

Genetic analysis of the human tumor necrosis factor alpha/cachectin promoter region in a macrophage cell line
Publicado: (1989)

Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway
Publicado: (1990)

Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease
Publicado: (1987)

A novel addition to the T cell repertory. Cell surface expression of tumor necrosis factor/cachectin by activated normal human T cells
Publicado: (1990)

Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor
Publicado: (1987)

Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors
Publicado: (1986)

Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins
Publicado: (1989)

Pretreatment with recombinant murine tumor necrosis factor alpha/cachectin and murine interleukin 1 alpha protects mice from lethal bacterial infection
Publicado: (1989)

Enhanced responsiveness of endothelium in the growing/motile state to tumor necrosis factor/cachectin [published erratum appears in J Exp Med 1989 Nov 1;170(5):1793]
Publicado: (1989)

Hydrazine sulfate protects D-galactosamine-sensitized mice against endotoxin and tumor necrosis factor/cachectin lethality: evidence of a role for the pituitary
Publicado: (1991)

Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level [published erratum appears in J Exp Med 1990 Mar 1;171(3):971-2]
Publicado: (1990)

Production of tumor necrosis factor/cachectin by human T cell lines and peripheral blood T lymphocytes stimulated by phorbol myristate acetate and anti-CD3 antibody
Publicado: (1988)

Localization of Urokinase‐type Plasminogen Activator, Plasminogen Activator Inhibitor‐1, 2 and Plasminogen in Colon Cancer
por: Naitoh, Hiroyuki, et al.
Publicado: (1995)

Vasoplegic syndrome in cardiac surgery: role of synergism between polymorphism of tumor necrosis factor beta and plasminogen activator inhibitor type 1
por: Iribarren, JL, et al.
Publicado: (2015)

Glucocorticoid-modulated gene expression of tissue- and urinary-type plasminogen activator and plasminogen activator inhibitor 1 and 2
Publicado: (1988)

The effects of residual platelets in plasma on plasminogen activator inhibitor-1 and plasminogen activator inhibitor-1-related assays
por: Pieters, Marlien, et al.
Publicado: (2017)

Vitamin D Deficiency is Associated With Increased Plasminogen Activator Inhibitor 1/Plasminogen Activator Inhibitor 2 Ratio in Pregnancy
por: Andersen, Matilde Kanstrup, et al.
Publicado: (2023)

Tissue plasminogen activator and plasminogen activator inhibitor type 1 gene polymorphism in patients with gastric ulcer complicated with bleeding.
por: Kim, Hong-Soo, et al.
Publicado: (2003)

Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation
por: Gupta, Kamlesh K., et al.
Publicado: (2017)

Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients
por: Zuo, Yu, et al.
Publicado: (2021)

Retraction: The effects of residual platelets in plasma on plasminogen activator inhibitor-1 and plasminogen activator inhibitor-1-related assays
Publicado: (2018)

Functional Stability of Plasminogen Activator Inhibitor-1
por: Yasar Yildiz, Songul, et al.
Publicado: (2014)

Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 Levels in Patients with Acute Paraquat Intoxication
por: Seok, Su-Jin, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_d2c3uo2c8u98269rn516gktjba